University of Colorado School of Medicine
USA
Dr. Klawitter joined iC42 in 2003 and holds the position of Associate Professor. Dr. Klawitter is a chemist trained at the Universität Bremen where she also received a Ph.D. in analytical chemistry and biochemistry. She has extensively utilized a combination of proteomics and metabolomics strategies for the discovery of molecular mechanisms underlying drug toxicity, cancerogenicity, the anti-cancer effects of drugs and drug resistance, as well as for the discovery and development of biomarkers as clinical diagnostic tools for individualized and predictive medicine. Currently, one of Dr. Klawitter’s main research goals is to deconvolute the complex interactions of genetics, diseases, environmental effects and immunosuppressant drug treatment on the development of endothelial dysfunction and resulting organ failure. In addition, Dr. Klawitter is an expert in regulatory compliance and has received her Master of Research Quality Assurance (MRQA) by the British Association for Research Quality Assurance. She currently serves as our laboratory Quality Assurance Officer.
Respiratroy Diseases,drug toxicity, cancerogenicity,anti-cancer effect of drugs,Biochemistry,genetics, diseases
Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report